S&P 500   3,870.29 (-0.81%)
DOW   31,391.52 (-0.46%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
S&P 500   3,870.29 (-0.81%)
DOW   31,391.52 (-0.46%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
S&P 500   3,870.29 (-0.81%)
DOW   31,391.52 (-0.46%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
S&P 500   3,870.29 (-0.81%)
DOW   31,391.52 (-0.46%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
Log in
OTCMKTS:OCPNY

Olympus Competitors

$21.62
+0.02 (+0.09 %)
(As of 03/2/2021 12:00 AM ET)
Add
Compare
Today's Range
$21.56
Now: $21.62
$22.15
50-Day Range
$18.17
MA: $20.08
$22.37
52-Week Range
$11.09
Now: $21.62
$22.99
Volume39,830 shs
Average Volume34,511 shs
Market Capitalization$29.64 billion
P/E Ratio77.21
Dividend Yield0.32%
Beta0.68

Competitors

Olympus (OTCMKTS:OCPNY) Vs. SNY, CSLLY, SYK, ISRG, GSK, and GILD

Should you be buying OCPNY stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Olympus, including Sanofi (SNY), CSL (CSLLY), Stryker (SYK), Intuitive Surgical (ISRG), GlaxoSmithKline (GSK), and Gilead Sciences (GILD).

Sanofi (NASDAQ:SNY) and Olympus (OTCMKTS:OCPNY) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, valuation, dividends and profitability.

Institutional and Insider Ownership

6.9% of Sanofi shares are owned by institutional investors. Comparatively, 0.1% of Olympus shares are owned by institutional investors. 1.0% of Sanofi shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Sanofi has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, Olympus has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500.

Profitability

This table compares Sanofi and Olympus' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sanofi14.49%24.77%13.28%
Olympus5.34%10.82%3.98%

Dividends

Sanofi pays an annual dividend of $1.17 per share and has a dividend yield of 2.5%. Olympus pays an annual dividend of $0.07 per share and has a dividend yield of 0.3%. Sanofi pays out 35.2% of its earnings in the form of a dividend. Olympus pays out 19.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Analyst Ratings

This is a breakdown of recent recommendations for Sanofi and Olympus, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sanofi14402.33
Olympus00014.00

Valuation & Earnings

This table compares Sanofi and Olympus' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sanofi$40.00 billion2.89$3.26 billion$3.3213.84
Olympus$7.32 billion4.05$475.36 million$0.3660.06

Sanofi has higher revenue and earnings than Olympus. Sanofi is trading at a lower price-to-earnings ratio than Olympus, indicating that it is currently the more affordable of the two stocks.

Summary

Sanofi beats Olympus on 10 of the 16 factors compared between the two stocks.

CSL (OTCMKTS:CSLLY) and Olympus (OTCMKTS:OCPNY) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, valuation, dividends and profitability.

Institutional and Insider Ownership

0.2% of CSL shares are owned by institutional investors. Comparatively, 0.1% of Olympus shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility & Risk

CSL has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. Comparatively, Olympus has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500.

Profitability

This table compares CSL and Olympus' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CSLN/AN/AN/A
Olympus5.34%10.82%3.98%

Dividends

CSL pays an annual dividend of $0.97 per share and has a dividend yield of 0.9%. Olympus pays an annual dividend of $0.07 per share and has a dividend yield of 0.3%. CSL pays out 42.0% of its earnings in the form of a dividend. Olympus pays out 19.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Analyst Ratings

This is a breakdown of recent recommendations for CSL and Olympus, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CSL03102.25
Olympus00014.00

Valuation & Earnings

This table compares CSL and Olympus' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CSL$9.15 billion10.55$2.10 billion$2.3145.94
Olympus$7.32 billion4.05$475.36 million$0.3660.06

CSL has higher revenue and earnings than Olympus. CSL is trading at a lower price-to-earnings ratio than Olympus, indicating that it is currently the more affordable of the two stocks.

Summary

Olympus beats CSL on 8 of the 15 factors compared between the two stocks.

Stryker (NYSE:SYK) and Olympus (OTCMKTS:OCPNY) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, valuation, dividends and profitability.

Volatility & Risk

Stryker has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Comparatively, Olympus has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500.

Valuation & Earnings

This table compares Stryker and Olympus' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stryker$14.88 billion6.20$2.08 billion$8.2629.71
Olympus$7.32 billion4.05$475.36 million$0.3660.06

Stryker has higher revenue and earnings than Olympus. Stryker is trading at a lower price-to-earnings ratio than Olympus, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations for Stryker and Olympus, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Stryker261412.61
Olympus00014.00

Stryker currently has a consensus target price of $231.00, indicating a potential downside of 5.86%. Given Stryker's higher probable upside, equities analysts clearly believe Stryker is more favorable than Olympus.

Dividends

Stryker pays an annual dividend of $2.52 per share and has a dividend yield of 1.0%. Olympus pays an annual dividend of $0.07 per share and has a dividend yield of 0.3%. Stryker pays out 30.5% of its earnings in the form of a dividend. Olympus pays out 19.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Stryker has raised its dividend for 1 consecutive years. Stryker is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Institutional and Insider Ownership

71.5% of Stryker shares are owned by institutional investors. Comparatively, 0.1% of Olympus shares are owned by institutional investors. 6.8% of Stryker shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Stryker and Olympus' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Stryker12.35%20.94%8.77%
Olympus5.34%10.82%3.98%

Summary

Stryker beats Olympus on 14 of the 17 factors compared between the two stocks.

Olympus (OTCMKTS:OCPNY) and Intuitive Surgical (NASDAQ:ISRG) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends.

Risk & Volatility

Olympus has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500.

Earnings & Valuation

This table compares Olympus and Intuitive Surgical's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Olympus$7.32 billion4.05$475.36 million$0.3660.06
Intuitive Surgical$4.48 billion19.71$1.38 billion$9.9575.38

Intuitive Surgical has lower revenue, but higher earnings than Olympus. Olympus is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings for Olympus and Intuitive Surgical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Olympus00014.00
Intuitive Surgical381002.33

Intuitive Surgical has a consensus price target of $736.75, indicating a potential downside of 1.77%. Given Intuitive Surgical's higher probable upside, analysts clearly believe Intuitive Surgical is more favorable than Olympus.

Insider & Institutional Ownership

0.1% of Olympus shares are owned by institutional investors. Comparatively, 86.5% of Intuitive Surgical shares are owned by institutional investors. 1.6% of Intuitive Surgical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Olympus and Intuitive Surgical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Olympus5.34%10.82%3.98%
Intuitive Surgical24.45%12.08%10.44%

Summary

Intuitive Surgical beats Olympus on 12 of the 15 factors compared between the two stocks.

Olympus (OTCMKTS:OCPNY) and GlaxoSmithKline (NYSE:GSK) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends.

Volatility and Risk

Olympus has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Comparatively, GlaxoSmithKline has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500.

Valuation and Earnings

This table compares Olympus and GlaxoSmithKline's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Olympus$7.32 billion4.05$475.36 million$0.3660.06
GlaxoSmithKline$43.10 billion1.98$5.93 billion$3.1710.75

GlaxoSmithKline has higher revenue and earnings than Olympus. GlaxoSmithKline is trading at a lower price-to-earnings ratio than Olympus, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings for Olympus and GlaxoSmithKline, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Olympus00014.00
GlaxoSmithKline33602.25

Dividends

Olympus pays an annual dividend of $0.07 per share and has a dividend yield of 0.3%. GlaxoSmithKline pays an annual dividend of $2.48 per share and has a dividend yield of 7.3%. Olympus pays out 19.4% of its earnings in the form of a dividend. GlaxoSmithKline pays out 78.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. GlaxoSmithKline has raised its dividend for 1 consecutive years. GlaxoSmithKline is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Institutional and Insider Ownership

0.1% of Olympus shares are held by institutional investors. Comparatively, 11.8% of GlaxoSmithKline shares are held by institutional investors. 10.0% of GlaxoSmithKline shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Olympus and GlaxoSmithKline's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Olympus5.34%10.82%3.98%
GlaxoSmithKline18.50%29.60%7.11%

Summary

GlaxoSmithKline beats Olympus on 11 of the 17 factors compared between the two stocks.

Olympus (OTCMKTS:OCPNY) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends.

Volatility and Risk

Olympus has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500.

Valuation and Earnings

This table compares Olympus and Gilead Sciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Olympus$7.32 billion4.05$475.36 million$0.3660.06
Gilead Sciences$22.45 billion3.53$5.39 billion$6.1410.26

Gilead Sciences has higher revenue and earnings than Olympus. Gilead Sciences is trading at a lower price-to-earnings ratio than Olympus, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings for Olympus and Gilead Sciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Olympus00014.00
Gilead Sciences1121202.44

Gilead Sciences has a consensus price target of $96.0370, indicating a potential upside of 52.42%. Given Gilead Sciences' higher probable upside, analysts clearly believe Gilead Sciences is more favorable than Olympus.

Dividends

Olympus pays an annual dividend of $0.07 per share and has a dividend yield of 0.3%. Gilead Sciences pays an annual dividend of $2.72 per share and has a dividend yield of 4.3%. Olympus pays out 19.4% of its earnings in the form of a dividend. Gilead Sciences pays out 44.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Gilead Sciences has raised its dividend for 1 consecutive years. Gilead Sciences is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Institutional and Insider Ownership

0.1% of Olympus shares are held by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Olympus and Gilead Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Olympus5.34%10.82%3.98%
Gilead Sciences5.48%37.77%12.76%

Summary

Gilead Sciences beats Olympus on 12 of the 18 factors compared between the two stocks.


Olympus Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Sanofi logo
SNY
Sanofi
1.6$45.94+0.1%$115.67 billion$40.00 billion19.63
CSL logo
CSLLY
CSL
1.0$106.13+0.3%$96.57 billion$9.15 billion45.94Increase in Short Interest
Stryker logo
SYK
Stryker
2.0$245.39+0.2%$92.32 billion$14.88 billion53.23Analyst Report
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.7$750.00+1.2%$88.29 billion$4.48 billion85.42
GlaxoSmithKline logo
GSK
GlaxoSmithKline
1.1$34.09+1.1%$85.52 billion$43.10 billion10.49Increase in Short Interest
Gilead Sciences logo
GILD
Gilead Sciences
2.8$63.01+0.9%$79.18 billion$22.45 billion64.96
Anthem logo
ANTM
Anthem
2.6$311.66+0.1%$76.33 billion$104.21 billion16.11
Zoetis logo
ZTS
Zoetis
2.1$157.05+0.4%$74.62 billion$6.26 billion46.60
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.4$244.73+0.5%$71.11 billion$17.12 billion89.64
Illumina logo
ILMN
Illumina
1.7$441.01+1.2%$64.34 billion$3.54 billion102.32
HCA Healthcare logo
HCA
HCA Healthcare
2.3$178.18+1.5%$60.57 billion$51.34 billion18.02Increase in Short Interest
Bayer Aktiengesellschaft logo
BAYRY
Bayer Aktiengesellschaft
1.0$15.82+0.0%$59.00 billion$48.23 billion-5.90Analyst Report
Increase in Short Interest
Gap Down
Moderna logo
MRNA
Moderna
1.6$146.81+7.2%$58.09 billion$60.21 million-90.62Earnings Announcement
Analyst Report
Insider Selling
Decrease in Short Interest
Analyst Revision
Boston Scientific logo
BSX
Boston Scientific
2.2$38.76+0.4%$55.50 billion$10.74 billion14.85Increase in Short Interest
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.4$212.06+0.8%$55.13 billion$4.16 billion26.78Analyst Upgrade
Takeda Pharmaceutical logo
TAK
Takeda Pharmaceutical
2.0$17.24+1.5%$54.35 billion$30.20 billion57.47
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.6$86.28+0.6%$53.88 billion$4.35 billion69.02Insider Selling
Increase in Short Interest
News Coverage
Humana logo
HUM
Humana
2.3$386.30+0.4%$49.78 billion$64.89 billion12.38Decrease in Short Interest
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$454.86+1.8%$48.73 billion$7.86 billion16.63Analyst Report
Lonza Group logo
LZAGY
Lonza Group
0.9$63.21+0.3%$47.07 billion$978.37 million46.14Analyst Upgrade
Increase in Short Interest
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$529.47+1.6%$45.23 billion$2.41 billion92.24
Align Technology logo
ALGN
Align Technology
2.0$563.21+0.3%$44.41 billion$2.41 billion25.62
Biogen logo
BIIB
Biogen
1.9$269.85+1.3%$41.11 billion$14.38 billion8.93
Baxter International logo
BAX
Baxter International
2.3$77.68+0.3%$39.24 billion$11.36 billion44.14
DexCom logo
DXCM
DexCom
1.7$391.91+1.2%$37.69 billion$1.48 billion161.95
EssilorLuxottica Société anonyme logo
ESLOY
EssilorLuxottica Société anonyme
1.4$82.74+0.4%$36.15 billion$19.48 billion33.63Upcoming Earnings
Analyst Report
Increase in Short Interest
News Coverage
Centene logo
CNC
Centene
2.1$59.14+0.4%$34.40 billion$74.64 billion16.47
Alcon logo
ALC
Alcon
1.2$70.43+0.0%$34.39 billion$7.51 billion-47.91Decrease in Short Interest
Analyst Revision
Zimmer Biomet logo
ZBH
Zimmer Biomet
2.1$161.19+1.4%$33.50 billion$7.98 billion1,007.50Analyst Report
Coloplast A/S logo
CLPBY
Coloplast A/S
1.0$15.42+0.3%$33.31 billion$2.76 billion55.07Increase in Short Interest
News Coverage
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.9$150.37+1.1%$33.06 billion$4.99 billion35.13Increase in Short Interest
News Coverage
Teladoc Health logo
TDOC
Teladoc Health
1.5$217.92+2.5%$31.59 billion$553.31 million-152.39Earnings Announcement
Analyst Revision
Astellas Pharma logo
ALPMY
Astellas Pharma
1.7$16.08+0.1%$29.94 billion$11.97 billion23.30Increase in Short Interest
(ALIOF) logo
ALIOF
(ALIOF)
0.4$278.50+0.0%$29.89 billionN/A0.00News Coverage
BeiGene logo
BGNE
BeiGene
1.1$306.46+4.2%$29.22 billion$428.21 million-15.16Earnings Announcement
Analyst Downgrade
Analyst Revision
Terumo logo
TRUMY
Terumo
0.8$38.12+1.4%$28.56 billion$5.79 billion37.01Upcoming Earnings
Decrease in Short Interest
Sunny Optical Technology (Group) logo
SNPTF
Sunny Optical Technology (Group)
0.5$25.68+1.2%$28.17 billion$5.48 billion0.00
ResMed logo
RMD
ResMed
1.4$193.21+1.2%$28.11 billion$2.96 billion41.46Insider Selling
Seagen logo
SGEN
Seagen
1.5$153.71+0.8%$27.85 billion$916.71 million60.52Decrease in Short Interest
McKesson logo
MCK
McKesson
2.4$173.72+0.0%$27.66 billion$231.05 billion13.22Analyst Report
Bitcoin Group logo
BTGGF
Bitcoin Group
0.5$68.80+0.0%$26.59 billionN/A0.00Increase in Short Interest
News Coverage
Takeda Pharmaceutical logo
TKPYY
Takeda Pharmaceutical
1.0$16.98+1.6%$26.53 billion$15.99 billion12.11
BioNTech logo
BNTX
BioNTech
0.9$104.98+5.0%$25.28 billion$121.63 million-52.49Decrease in Short Interest
Fresenius SE & Co. KGaA logo
FSNUY
Fresenius SE & Co. KGaA
1.6$10.85+0.1%$24.14 billion$39.66 billion11.92Earnings Announcement
Decrease in Short Interest
Laboratory Co. of America logo
LH
Laboratory Co. of America
1.6$243.65+0.9%$23.73 billion$11.55 billion28.36
Exact Sciences logo
EXAS
Exact Sciences
1.6$136.39+2.8%$23.06 billion$876.29 million-61.71Analyst Upgrade
Sysmex logo
SSMXY
Sysmex
0.6$53.67+0.8%$22.21 billion$2.78 billion81.32Upcoming Earnings
Increase in Short Interest
News Coverage
Genmab A/S logo
GMAB
Genmab A/S
1.5$33.83+3.8%$22.17 billion$804.57 million26.23Increase in Short Interest
Analyst Revision
Sino Biopharmaceutical logo
SBMFF
Sino Biopharmaceutical
0.8$1.20+5.0%$21.53 billion$3.51 billion0.00Gap Down
MKGAF
MERCK Kommanditgesellschaft auf Aktien
0.5$164.60+1.1%$21.52 billion$18.09 billion0.00Upcoming Earnings
This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.